Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Novartis presents phase IIa data for BPS-804

April 24, 2017

Parvus signs license and collaboration agreement with Novartis in type 1 diabetes

April 20, 2017

Encouraging 24-week data reported from phase III study of burosumab in X-linked hypophosphatemia

April 19, 2017

BioSpecifics opens phase I study of Xiaflex for uterine fibroids

April 19, 2017

Oxandrolone induces early puberty in boys with Klinefelter syndrome

April 18, 2017

XOMA tests anti-PTH1R human monoclonal antibodies in vitro and in rodent models

April 13, 2017

Medix obtains approval to initiate phase III study of tesofensine

April 12, 2017

AzurRx Biopharma's phase II study of MS-1819 expected to complete Q3 2017

April 12, 2017

TherapeuticsMD gives update on TX-004HR NDA

April 11, 2017

BGS-649 normalizes testosterone levels in patients with secondary hypogonadotropic hypogonadism

April 11, 2017

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 9, 2026.
Hengrui discovers new Nav1.8 blockers
BioWorld Science
Researchers from Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have patented new sodium channel protein type 10 subunit α...
Hematopoietic stem cell research points to leukemia’s early roots
BioWorld Science
Hematopoietic stem cell (HSC) research over the past century has shown that leukemia may be driven by an invisible hand of inflammation. The bone marrow and...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 7, 2026
Lilly shifts from obesity to narcolepsy with $7.8B Centessa buy
BioWorld
Eli Lilly and Co. plans to buy Centessa Pharmaceuticals plc for $6.3 billion in up-front cash and another potential $1.5 billion through contingent value rights,...